Review of calciphylaxis and treatment of a severe case after kidney transplantation with iloprost in combination with hyperbaric oxygen and cultured autologous fibrin-based skin substitutes.
Calciphylaxis, also known as calcific uremic arteriolopathy (CUA), is a rare complication in patients with end-stage renal disease as well as in patients after renal transplantation. It should be suspected in patients with typical painful violaceous skin lesions on the extremities or on the trunk. Active multidisciplinary management approach, with intensive local wound care, is vital in these patients. Controlling parathyroid hormone, hyperbaric oxygenation, sodium thiosulphate, bisphosphonates, cinacalcet and skin grafting could be effective. In our report, we describe a case of CUA in a 43-year-old patient two years after kidney transplantation. Despite intensive standard treatment, his wounds progressed; therefore, we decided to use iloprost, in combination with hyperbaric oxygenation. The clean wounds were then covered with cultivated autologous skin cells to enhance wound epithelialization. Seven months after finishing iloprost and hyperbaric oxygen treatment and the first application of skin substitute, the wounds healed completely and remained healed during the four-yr follow-up period. We conclude that in patients with severe CUA-induced wounds, the combined treatment with iloprost, hyperbaric oxygen and autologous cultured fibrin-based skin substitutes can be effective. A combination of different treatment modalities is vital in patients with CUA.
Alikadic
Nadja
N
Department of Surgical Infections, University Medical Centre Ljubljana, Slovenia.
Kovac
Damjan
D
Krasna
Metka
M
Lindic
Jelka
J
Sabovic
Miso
M
Tomazic
Janez
J
Jeras
Matjaz
M
Smrke
Dragica
D
D000328:Adult; D002115:Calciphylaxis / Q000209:etiology / Q000628:therapy*; D017690:Cell Transplantation / Q000379:methods; D002478:Cells, Cultured; D005337:Fibrin / Q000494:pharmacology*; D006801:Humans; D006931:Hyperbaric Oxygenation / Q000379:methods*; D016285:Iloprost / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D012720:Severity of Illness Index; D012867:Skin / Q000166:cytology*; D017768:Skin, Artificial; D014665:Vasodilator Agents / Q000627:therapeutic use
D014665:Vasodilator Agents; D005337:Fibrin; D016285:Iloprost